The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Hepatitis C as a predictor of treatment outcome in patients with hepatocellular carcinoma treated with the retinoid derivative, TAC-101.
Vikesh Khanijow
Disclosure not yet available
Ahmed Omar Kaseb
Disclosure not yet available
Manal Hassan
Disclosure not yet available
Victor I. Machicao
Disclosure not yet available
Hesham Mohamed Hassabo
Disclosure not yet available
James L. Abbruzzese
Disclosure not yet available